CoChat
Sign Up
Cited by 118

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Risk of Drug-Induced Liver Injury From Tumor Necrosis Factor Antagonists

Björnsson, Einar S., Gunnarsson, Baldvin I., Gröndal, Gerdur, Jonasson, Jon G., Einarsdottir, Rannveig, Ludviksson, Björn R., Gudbjörnsson, Björn, Olafsson, Sigurdur·2015·Clinical Gastroenterology and Hepatology
DOI 10.1016/j.cgh.2014.07.062
Open this paper in CoChat — free account

Abstract

Background & aims Antagonists of tumor necrosis factor (anti-TNF agents) can cause drug-induced liver injury (DILI), yet little is known about the level of risk. Methods We identified cases of DILI caused by anti-TNF agents in Iceland, from 2009 through 2013, at the National University Hospital of Iceland (n = 11). We collected data on the total use of the drugs by patients with DILI, and outcomes, compared with patients who received anti-TNF agents but who did not develop DILI (controls, n = 22). Results Of the 11 cases of DILI identified (8 women; mean age, 46 y), 9 cases were caused by infliximab. DILI developed in 1 of 120 patients who received infliximab, 1 in 270 patients who received adalimumab, and 1 in 430 patients who received etanercept. Most patients with infliximab-associated DILI developed this disorder after 4 infusions (n = 6). Four patients had jaundice at diagnosis of DILI, and 8 patients had hepatocellular liver injury. The mean peak level of alanine aminotransferase was 704 U/L, of aspartate aminotransferase was 503 U/L, of alkaline phosphatase was 261 U/L, and of bilirubin was 47 μmol/L. Seven patients with DILI were tested for antinuclear antibodies before therapy with an anti-TNF agent and 3 had positive test results, compared with 5 of the 14 controls tested. At DILI diagnosis, 8 of 11 patients tested positive for antinuclear antibodies. Of liver biopsy specimens collected from 5 patients with DILI, 3 showed signs of severe acute hepatitis. Only 9% of…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2014.07.062

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 23

  1. Menghini, 2001, Infliximab-associated reversible cholestatic liver disease, Mayo Clin Proc, 76, 84, 10.4065/76.1.84 · DOI
  2. Saleem, 2001, Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles, et al, Arthritis Rheum, 44, 1966, 10.1002/1529-0131(200108)44:8<1966::AID-ART339>3.0.CO;2-3 · DOI
  3. Germano, 2005, Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis, Ann Rheum Dis, 64, 1519, 10.1136/ard.2004.032821 · DOI
  4. Tobon, 2007, Serious liver disease induced by infliximab, Clin Rheumatol, 26, 578, 10.1007/s10067-005-0169-y · DOI
  5. Harada, 2008, A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis, Clin Rheumatol, 27, 1063, 10.1007/s10067-008-0885-1 · DOI
  6. Thiéfin, 2008, Infliximab-induced hepatitis: absence of cross-toxicity with etanercept, Joint Bone Spine, 75, 737, 10.1016/j.jbspin.2007.12.009 · DOI
  7. Ozorio, 2007, Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis, Med J Aust, 187, 524, 10.5694/j.1326-5377.2007.tb01396.x · DOI
  8. Goujon, 2010, Autoimmune hepatitis in two psoriasis patients treated with infliximab, J Am Acad Dermatol, 63, e43, 10.1016/j.jaad.2009.02.029 · DOI
  9. Adar, 2010, Adalimumab-induced autoimmune hepatitis, J Clin Gastroenterol, 44, e20, 10.1097/MCG.0b013e3181a745e7 · DOI
  10. Haennig, 2010, Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab, Gastroenterol Clin Biol, 34, e7, 10.1016/j.gcb.2010.01.016 · DOI
  11. Poulin, 2010, Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review, J Cutan Med Surg, 14, 100, 10.2310/7750.2009.09007 · DOI
  12. Grasland, 2012, Autoimmune hepatitis induced by adalimumab with successful switch to abatacept, Eur J Clin Pharmacol, 68, 895, 10.1007/s00228-011-1191-4 · DOI
  13. Ghabril, 2013, Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases, Clin Gastroenterol Hepatol, 11, 558, 10.1016/j.cgh.2012.12.025 · DOI
  14. De Rycke, 2005, Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis, Arthritis Rheum, 52, 2192, 10.1002/art.21190 · DOI
  15. Takase, 2014, What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort, Ann Rheum Dis, 73, 1695, 10.1136/annrheumdis-2014-205318 · DOI
  16. Danan, 1993, Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  17. Vander Cruyssen, 2005, DAS28 best reflects the physician’s clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment, Arthritis Res Ther, 7, R1063, 10.1186/ar1787 · DOI
  18. Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury (DILI). Search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI
  19. Lucena, 2009, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex, Hepatology, 49, 2001, 10.1002/hep.22895 · DOI · Paper page
  20. Hennes, 2008, Simplified criteria for the diagnosis of autoimmune hepatitis, Hepatology, 48, 169, 10.1002/hep.22322 · DOI · Paper page
  21. Björnsson, 2010, Drug-induced autoimmune hepatitis: clinical characteristics and prognosis, Hepatology, 51, 2040, 10.1002/hep.23588 · DOI · Paper page
  22. Boehm, 1998, Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms, Rheumatol Int, 18, 59, 10.1007/s002960050058 · DOI
  23. Vergani, 2003, Autoimmune hepatitis, Autoimmun Rev, 2, 241, 10.1016/S1568-9972(03)00017-X · DOI

Cited by

Sorted by citations

Metadata

Authors
Björnsson, E. S., Gunnarsson, B. I., Gröndal, G., Jonasson, J. G., Einarsdottir, R., Ludviksson, B. R., Gudbjörnsson, B., & Olafsson, S.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2015-03
Volume
13
Issue
3
Pages
602-608
ISSN
1542-3565
DOI
10.1016/j.cgh.2014.07.062
Cited by
118
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review